Prevalence of Hemolytic Uremic Syndrome (HUS) in Pediatrics
Ориентир для пациента и семьи
Простыми словами
Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.
- Что изучают
- Это наблюдательное исследование: исследуемое лечение участникам по протоколу не назначают.
- Кому может быть актуально
- Состояния в реестре: Prevalence of Hemolytic Uremic Syndrome. Базовые параметры: 1 Day — 18 лет · Все.
- Что важно проверить
- Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
- Где проводится
- Список центров уточняется — проверьте первичный протокол.
- Следующий шаг
- Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Не всё понятно в терминах? Прочитайте наш гид для пациентов →
Официальное название
Prevalence of Hemolytic Uremic Syndrome (HUS) in Pediatrics at Assiut University Children's Hospital: A Prospective Study
Обзор
To determine the prevalence of hemolytic uremic syndrome (HUS) among pediatric patients admitted to Assiut University Children's Hospital, and to describe the demographic, clinical, and laboratory characteristics of the affected population.
Подробное описание
Hemolytic uremic syndrome (HUS) is a rare but serious condition characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. \[1\] Two main subtypes of HUS are recognized. The majority of pediatric cases are classified as typical HUS, most frequently associated with Shiga toxin-producing Escherichia coli (STEC) infection. In contrast, atypical HUS (aHUS) is less common, accounting for approximately 5-10% of cases, and is linked to dysregulation of the complement system. The clinical course and prognosis differ significantly between these subtypes.\[2\].
Understanding the prevalence of HUS is critical for early recognition and timely intervention, especially in resource-limited settings. \[3\] Complications of HUS can be severe and include neurological manifestations, hypertension, persistent renal impairment, and in some cases, death. Early diagnosis and supportive care are critical for improved outcomes \[4\].
Local factors such as water safety, sanitation, access to early antibiotics, and public health surveillance greatly affect the observed prevalence. \[5\] The management of typical HUS caused by STEC is generally supportive. \[6\] For aHUS, early treatment is crucial to avoid end-stage renal disease (ESRD) and mortality. The cornerstones of treatment for aHUS are first-line therapy with eculizumab \[7\]
Первичные конечные точки
- Prevalence of Hemolytic Uremic Syndrome (HUS) among Pediatric Patients [Срок оценки: Within 12months of enrollment (october 2025-September 2026)]
Критерии участия
Критерии включения
- Patients aged below 18 years at the time of diagnosis.
- Confirmed diagnosis of HUS based on the clinical triad (microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury).
Критерии исключения
- Patients aged 18 years or above at the time of diagnosis.
- Incomplete or missing medical records that do not confirm the diagnosis.
Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.
Дизайн исследования
- Модель наблюдения
- Другое
Центры проведения
Список центров уточняется — проверьте первичный протокол.
Публикации
- Franchini M. Atypical hemolytic uremic syndrome: from diagnosis to treatment. Clin Chem Lab Med. 2015 Oct;53(11):1679-88. doi: 10.1515/cclm-2015-0024. PMID 25803082
- Joseph A, Cointe A, Mariani Kurkdjian P, Rafat C, Hertig A. Shiga Toxin-Associated Hemolytic Uremic Syndrome: A Narrative Review. Toxins (Basel). 2020 Jan 21;12(2):67. doi: 10.3390/toxins12020067. PMID 31973203
- Jenssen GR, Hovland E, Bjerre A, Bangstad HJ, Nygard K, Vold L. Incidence and etiology of hemolytic-uremic syndrome in children in Norway, 1999-2008--a retrospective study of hospital records to assess the sensitivity of surveillance. BMC Infect Dis. 2014 May 16;14:265. doi: 10.1186/1471-2334-14-265. PMID 24884396
- Yerigeri K, Kadatane S, Mongan K, Boyer O, Burke LLG, Sethi SK, Licht C, Raina R. Atypical Hemolytic-Uremic Syndrome: Genetic Basis, Clinical Manifestations, and a Multidisciplinary Approach to Management. J Multidiscip Healthc. 2023 Aug 4;16:2233-2249. doi: 10.2147/JMDH.S245620. eCollection 2023. PMID 37560408
- Zagozdzon I, Szczepanska M, Leszczynska B, Jarmuzek W, Miklaszewska M, Tkaczyk M, Medynska A, Wieczorkiewicz-Plaza A, Zachwieja J, Protas P, Rosinska P, Jacher U, Trembecka-Dubel E, Zwolinska D, Zurowska A. Changing Epidemiology and Outcomes of Hemolytic Uremic Syndrome in Children: A Prospective National Cohort Study from the Polish Pediatric HUS Registry and the Polish Registry of Renal Replacem PMID 39518638
- McKee RS, Schnadower D, Tarr PI, Xie J, Finkelstein Y, Desai N, Lane RD, Bergmann KR, Kaplan RL, Hariharan S, Cruz AT, Cohen DM, Dixon A, Ramgopal S, Rominger A, Powell EC, Kilgar J, Michelson KA, Beer D, Bitzan M, Pruitt CM, Yen K, Meckler GD, Plint AC, Bradin S, Abramo TJ, Gouin S, Kam AJ, Schuh A, Balamuth F, Hunley TE, Kanegaye JT, Jones NE, Avva U, Porter R, Fein DM, Louie JP, Freedman SB; Pe PMID 31125419
- Bayer G, von Tokarski F, Thoreau B, Bauvois A, Barbet C, Cloarec S, Merieau E, Lachot S, Garot D, Bernard L, Gyan E, Perrotin F, Pouplard C, Maillot F, Gatault P, Sautenet B, Rusch E, Buchler M, Vigneau C, Fakhouri F, Halimi JM. Etiology and Outcomes of Thrombotic Microangiopathies. Clin J Am Soc Nephrol. 2019 Apr 5;14(4):557-566. doi: 10.2215/CJN.11470918. Epub 2019 Mar 12. PMID 30862697
- Beczkiewicz ATE, Scharff RL, Kowalcyk BB. Facilitating Evaluation of Hemolytic Uremic Syndrome Long-Term Health Outcomes Through Social Media Support Groups. Front Public Health. 2020 Nov 23;8:544154. doi: 10.3389/fpubh.2020.544154. eCollection 2020. PMID 33330302
Идентификаторы
NCT: NCT07171749 · Prevelance of HUS